Daily Archives: August 28, 2026

Aficamten Improves Exercise Capacity and Health Status in Nonobstructive HCM

This entry was posted in Cardiovascular Diseases and tagged Aficamten Efficacy HCM Nonobstructive Safety on

In patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), aficamten significantly improved exercise capacity and patient-reported health status compared with placebo at 36 weeks. In this phase 3 multinational, double-blind trial, 517 adults were randomly assigned to receive aficamten or placebo for up to 72 weeks. At week 36, the Kansas […]

DOACs Reduce Cardiovascular Events in Atrial Fibrillation at Intermediate Stroke Risk

This entry was posted in Cardiovascular Diseases and tagged Atrial Fibrillation DOAC Efficacy Intermediate Stroke Risk Safety on

In patients with atrial fibrillation at intermediate risk for stroke, direct oral anticoagulant (DOAC) therapy significantly reduced the 24-month risk of a composite of stroke, systemic embolism, major bleeding, or cardiovascular death compared with no anticoagulation. In the Korean multicenter, open-label, adjudicator-masked randomized trial, 1,803 patients with a CHA₂DS₂-VASc score […]